{"id":258610,"date":"2020-06-19T02:40:35","date_gmt":"2020-06-19T06:40:35","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=258610"},"modified":"2025-01-12T15:21:45","modified_gmt":"2025-01-12T20:21:45","slug":"the-steroid-dexamethasone-is-the-first-drug-shown-to-reduce-covid-19-deaths","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2020\/06\/19\/the-steroid-dexamethasone-is-the-first-drug-shown-to-reduce-covid-19-deaths\/","title":{"rendered":"The steroid dexamethasone is the first drug shown to reduce COVID-19 deaths"},"content":{"rendered":"
\"\"<\/a>
Dexamethasone, a steroid in use for decades,\u00a0reduced deaths\u00a0of COVID-19 patients on ventilators by about a third compared with standard care, researchers reported in a news release June 16. Deaths of COVID-19 patients on supplemental oxygen were reduced by about 20 percent. (Pixabay photo)<\/figcaption><\/figure>\n

A low-cost steroid may save the lives of some people who are on ventilators or supplemental oxygen because of COVID-19, preliminary data from a large clinical trial suggest.<\/p>\n

Dexamethasone, a steroid in use for decades,\u00a0reduced deaths<\/a>\u00a0of COVID-19 patients on ventilators by about a third compared with standard care, researchers reported in a news release June 16. Deaths of COVID-19 patients on supplemental oxygen were reduced by about 20 percent. Researchers found no benefit for hospitalized patients who didn\u2019t need extra oxygen.<\/p>\n

If the results hold up to scrutiny once scientists have a chance to review the full data, the drug would be the first to reduce the risk of death from the disease. For many patients who wind up in the hospital with COVID-19, \u201cquestion one is, \u2018Will I survive?\u2019 and question two is \u2018How long will I have to stay in hospital?\u2019 This is the first drug that says, yes, we can increase your chances of survival,\u201d says Martin Landray, a cardiologist at the University of Oxford. Another drug,\u00a0remdesivir, has been shown to shorten recovery time<\/a>\u00a0for seriously ill patients (SN: 5\/13\/20<\/em>).<\/p>\n

The new finding was based on outcomes of 2,104 patients taking 6 milligrams of dexamethasone once a day for 10 days either as a tablet or by intravenous injection and 4,321 people not taking the drug. The study was stopped early once a steering committee felt enough patients had been enrolled in this segment of the study to determine whether the drug worked or not. Landray and colleagues discovered that taking dexamethasone could prevent one death for every eight patients on ventilation, and one death for every 25 patients needing extra oxygen.<\/p>\n

\u201cIt\u2019s not a fix. It\u2019s not a cure. It\u2019s not a miracle, but it is really, really useful,\u201d Landray says. He expects doctors around the world will embrace the therapy.<\/p>\n

buy periactin online https:\/\/pelmeds.com\/wp-content\/uploads\/2024\/08\/jpg\/periactin.html<\/a> no prescription pharmacy <\/div>\n

He says that the United Kingdom\u2019s National Health Service may soon declare dexamethasone the standard treatment for people on ventilators because of COVID-19.<\/p>\n

buy soft cialis online https:\/\/pelmeds.com\/wp-content\/uploads\/2024\/08\/jpg\/soft-cialis.html<\/a> no prescription pharmacy <\/div>\n

<\/p>\n

\u201cThese are potentially very exciting data,\u201d says Rajesh Gandhi, an infectious diseases doctor at Massachusetts General Hospital and Harvard Medical School in Boston. He has helped write COVID-19 treatment guidelines for the U.S. National Institutes of Health and for the Infectious Diseases Society of America, but says he will wait until he sees the full report to decide whether the results warrant changing treatment of severely ill patients. \u201cRight now we have very limited information, but if it\u2019s borne out it could be really exciting.\u201d<\/p>\n

Although the results are important for treating the sickest patients with COVID-19, those patients represent only about 5 percent of people diagnosed with the coronavirus, Gandhi says. \u201cIt\u2019s not steroids for all.\u201d<\/p>\n

For the majority of patients, the drug probably would not do any good and may even do harm. Dexamethasone and other steroids dampen the immune system\u2019s response to invading organisms, and have been shown to make viral infections, such as influenza and SARS worse. Researchers thought that if steroids worsened SARS, it might do the same for SARS-CoV-2, the coronavirus that causes COVID-19. Treatment guidelines suggest doctors not use steroids against the novel coronavirus.<\/p>\n

The way the results were released has some scientists worried that they may not hold up.<\/p>\n

buy zydena online https:\/\/pelmeds.com\/wp-content\/uploads\/2024\/08\/jpg\/zydena.html<\/a> no prescription pharmacy <\/div>\n

\u201cWe\u2019ve all seen preprints and press releases about other potential therapies that have not borne out to be true,\u201d says Brian Garibaldi, director of the biocontainment unit at Johns Hopkins Medicine.<\/p>\n

Landray says he understands the criticism, but felt it was important to \u201cget the results out into the public domain so that they\u2019re no longer my little secrets, the world at large can see them and make their decisions.\u201d<\/p>\n

He and colleagues are writing a scientific paper with more details, but it will take time for the study to be reviewed and published. Meanwhile, he says, \u201cthe drug is already sitting in hospitals now \u2014 it doesn\u2019t cost much money and the benefits are really obvious \u2014 and it can be used worldwide and you\u2019re in the middle of a pandemic.\u201d<\/p>\n

Garibaldi says he\u2019s hopeful that the results will hold up. \u201cCertainly to have something that would reduce mortality would be a game changer,\u201d he says, but doctors are unlikely to alter treatments for their patients based on the limited data presented. \u201cWhen I go into the ICU next week, I don\u2019t plan on using dexamethasone unless I can see the data and we can discuss it as a critical care community.\u201d<\/p>\n

\n

CITATIONS<\/em><\/h3>\n

RECOVERY trial investigators.\u00a0Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19<\/a>. June 16, 2020.<\/em><\/p>\n

This article<\/a> is originally published on Science News<\/a>.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

A low-cost steroid may save the lives of some people who are on ventilators or supplemental oxygen because of COVID-19, …<\/p>\n","protected":false},"author":44,"featured_media":258611,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-258610","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","mauthors-tina-hesman-saey","mauthors-science-news"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/258610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=258610"}],"version-history":[{"count":2,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/258610\/revisions"}],"predecessor-version":[{"id":282861,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/258610\/revisions\/282861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/258611"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=258610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=258610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=258610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}